Cerebrospinal fluid lipoproteins in Alzheimer's disease

被引:0
|
作者
Bassett, CN
Montine, KS
Neely, MD
Swift, LL
Montine, TJ
机构
[1] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA
[2] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA
[3] Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA
关键词
cerebrospinal fluid; apolipoproteins; Alzheimer's disease;
D O I
10.1002/1097-0029(20000815)50:4<282::AID-JEMT6>3.0.CO;2-T
中图分类号
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号
100101 ;
摘要
Interest in cerebrospinal fluid (CSF) lipoproteins has been stimulated by the association of certain alleles of the human apolipoprotein E gene (APOE) with an increased risk of Alzheimer's disease (AD), and because apolipoprotein E (apoE) is one of the major apolipoproteins in CSF. CSF lipoproteins (d < 1.210 g/ml fraction) are distinct from their plasma counterparts, and in AD patients CSF may contain novel particles. The protein concentration of CSF lipoproteins is reduced in AD patients. Moreover, the molecular distribution of apoE- and apoAII-containing apolipoproteins in CSF is dictated by APOE. The lipid composition suggests that CSF lipoproteins from AD patients may have undergone increased free radical-mediated damage; experimental data support the possibility that this may occur both before and after lipoprotein assembly. Finally, human CSF lipoproteins oxidized ex vivo are neurotoxic to neuronal cells in culture and disrupt microtubule structure, an activity not observed with oxidized bovine CSF lipoproteins. CSF lipoproteins may represent a means whereby apoE influences the outcome of free radical-mediated damage to brain. (C) 2000 Wiley-Liss, Inc.
引用
下载
收藏
页码:282 / 286
页数:5
相关论文
共 50 条
  • [1] Cerebrospinal fluid biomarkers of Alzheimer’s disease
    Xiaojing Sui
    Jianjun Liu
    Xifei Yang
    Neuroscience Bulletin, 2014, 30 : 233 - 242
  • [2] Cerebrospinal fluid biomarkers of Alzheimer's disease
    Fagan, Anne M.
    Holtzman, David M.
    BIOMARKERS IN MEDICINE, 2010, 4 (01) : 51 - 63
  • [3] Cerebrospinal fluid biomarkers in Alzheimer's disease
    Hugon, Jacques
    Dumurgier, Julien
    Cognat, Emmanuel
    Paquet, Claire
    BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE, 2018, 202 (1-2): : 307 - 318
  • [4] Cerebrospinal Fluid Biomarkers for Alzheimer's Disease
    Blennow, Kaj
    Zetterberg, Henrik
    JOURNAL OF ALZHEIMERS DISEASE, 2009, 18 (02) : 413 - 417
  • [5] Cerebrospinal fluid shunting for Alzheimer's disease?
    Bennett, DA
    McDermott, MP
    NEUROLOGY, 2002, 59 (08) : 1126 - 1127
  • [6] Cerebrospinal fluid biomarkers of Alzheimer's disease
    Sui, Xiaojing
    Liu, Jianjun
    Yang, Xifei
    NEUROSCIENCE BULLETIN, 2014, 30 (02) : 233 - 242
  • [7] Cerebrospinal fluid biomarkers in Alzheimer's disease
    Lee, K. H.
    JOURNAL OF NEUROCHEMISTRY, 2013, 125 : 41 - 42
  • [8] Cerebrospinal fluid biomarkers of Alzheimer's disease
    Xiaojing Sui
    Jianjun Liu
    Xifei Yang
    Neuroscience Bulletin, 2014, 30 (02) : 233 - 242
  • [9] Association of cerebrospinal fluid Neurogranin with Alzheimer’s disease
    Lijun Wang
    Aging Clinical and Experimental Research, 2019, 31 : 185 - 191
  • [10] Cerebrospinal fluid lipidomics for biomarkers of Alzheimer's disease†
    Byeon, Seul Kee
    Madugundu, Anil K.
    Jain, Ankit P.
    Bhat, Firdous A.
    Jung, Jae Hun
    Renuse, Santosh
    Darrow, Jacqueline
    Bakker, Arnold
    Albert, Marilyn
    Moghekar, Abhay
    Pandey, Akhilesh
    MOLECULAR OMICS, 2021, 17 (03) : 454 - 463